Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/364803


Drugs in the Pipeline--An R&D Analysis


Description:

Functional Genomics Provides Easy Target Identification and Improved Drug Discovery

Functional genomics and proteomics have been quite successful in identifying the function of potential therapeutic targets, such as encoded proteins. In fact, the possible identification of 10,000 novel target antigens in the human genome signals accelerated discovery of new drugs and therapeutic molecules. As opposed to conventional sequence homology, functional genomics adds structure-based predictions to locate gene sequences with assigned and confirmed functions. It simultaneously sifts through well established targets to detect critical therapeutic targets. Such structural information results in enriched annotations that improve the identification process and also provides a clearer understanding of interactions between specific molecules and target proteins. Moreover, functional genomics is likely to bring in a higher level of efficiency to clinical research with the possibilities of genetically demarcating patients and predicting individual responses to drugs. This permits customized medications and dosages for each patient, ultimately improving treatment safety and efficacy in areas such as neuropsychiatry, cardiovascular medicine, endocrinology, and oncology.

This Frost & Sullivan research analyzes the drugs in the research and development pipelines for prominent ailments in the cardiovasular, central nervous system, and cancer therapeutic areas. Analysis of the technological trends, drivers, challenges, and recent developments assists in creating effective R&D, marketing and production strategies. The research service also discusses enabling technologies such as nanotechnology, microdosing and drug absorption studies that may be useful in accelerating early phase drug discovery efforts. Participants can identify potential collaborators, stay ahead of the competition, and stay shoulder-to-shoulder with critical developments in their respective therapeutic segments.

Increasing Requirement for Target Specificity Challenges Drug Discovery

Lead identification proves to be an important component of drug discovery wherein a lead compound or molecule with the potential to treat a disease is located and tested to confirm its effect on the drug target. However, the primary quest in drug discovery is ‘target specificity,’ which goes beyond mere determination of lead compounds. The more precisely a lead compound interacts with its intended target, the greater its ability to produce the desired therapeutic effect, explains the analyst. Tissue selectivity and intracellular localization are fast becoming essential criteria in selecting lead compounds for promising therapeutic agents.

Demand for Drugs with Reduced Side Effects Challenges Drug Development

With a wide range of therapeutic options available, the benefit-risk ratio may be the key determinant of a drug's prescription in clinical practice, says the analyst. The goal is to identify and eliminate potential side effects produced by compounds and develop therapies with the least side effects for a desired action. The urgency to alleviate side effects may be particularly valid in the case of lifetime illnesses such as schizophrenia that require long-term antipsychotic treatment. This has catalyzed research for drugs that lower motor side effects such as tardive dyskinesia. Exciting new developments may be witnessed in breast cancer therapies where long-term chemotherapy necessitates drugs that alleviate harmful side effects from over exposure to radiation. For instance, hematopoietic stem cells that generate new blood cells to replace those killed by chemotherapy are being tested with metastatic breast cancer patients.


Contents: 1 EXECUTIVE SUMMARY

Introduction

The Drug Discovery Process

Pre-Clinical Studies

Overview of Clinical Trials

Scope and Methodology

Scope and Segmentation

Methodology

2 MARKET- AND TECHNOLOGY-BASED ANALYSIS
Challenges; Drivers; Restraints

Drug Discovery Technology Restraints

Drug Discovery Market Restraints

Technology and Market Drivers

Profiles of Drug Development Industry Partnerships and Collaborations - I

Profiles of Drug Development Industry Partnerships and Collaborations - II

Profiles of Drug Development Industry Partnerships and Collaborations - III

New Technologies and Research Related Impacting Drug Discovery

Microdosing Accelerates Early-Phase Drug Development

Using Nanotechnology to Enhance the Pharmacological Profile and Extend Exclusivity of Drugs

Human Drug Absorption Studies Enhance Candidate Selection

Drug Distribution Studies Use Gamma Scintigraphy
Advances in Drug Delivery--Injection Technologies; Inhalation Delivery
Advances in Drug Delivery--Targeted Delivery; Liposomes; Microencapsulation
Advances in Drug Delivery--Polymers; Nanotechnology-MEMS-Microchips

Dynamic Combinatorial Chemistry

Rationalization of Target Selection

3 DRUGS IN THE PIPELINE FOR THE CARDIOVASCULAR SYSTEM

Cardiovascular Therapeutics Research in the Universities

Gene Linked to Coronary Artery Disease and Myocardial Infarction Discovered
Blood Protein's Link to Heart Disease

Corporate Research in Cardiovascular Therapeutics

deCODE genetics Finds Heart Attack Risk Gene

Hedgehog Gene for Easing Heart Attack

Nicotine Boosts Stem Cell Production

Celera Finds Heart Attack Marker

Drugs in The Pipeline for Cardiovascular Disorders

Overview of Cardiovascular Disorders

Drugs in the Pipeline for Heart Failure

Drugs in the Pipeline for Hypertension

Drugs in the Pipeline for Coronary Thrombosis

Drugs in the Pipeline for Arrhythmia

Drugs in the Pipeline for Deep Vein Thrombosis

Drugs in the Pipeline for Ischemic Stroke

Drugs in the Pipeline for Coronary Artery Disease

Drugs in the Pipeline for Dyslipidemia

Drugs in the Pipeline for Angina

Drugs in the Pipeline for Myocardial Infarction

Adjunctive Therapies

4 DRUGS IN THE PIPELINE FOR THE CENTRAL NERVOUS SYSTEM

Corporate Research in CNS Therapeutics
AGY Therapeutics Finds Cathepsin B in Alzheimer's

BAFF Structure Aids Xencor Anti-TNF Agent Search

Nexia Nerve Protection Agent Meets Army Objective

Repligen Autism Clinical Does Not Meet Endpoints

deCode Begins Study of Autism Genetics
Depression/Anxiety Drug Milestone for Neurogen
MorphoSys Antibodies Hit Alzheimer’s Brain Target
Targacept Finds Alzheimer’s Cell Death Gene

University Research in CNS Therapeutics

Activated Protein C Protects Brain Cells
Pittsburgh Compound Offers a Peep into Alzheimer's Disease

Drugs in the Pipeline for CNS Disorders

CNS Disorder Overview
Drugs in the Pipeline for Alzheimer’s Disease
Drugs in the Pipeline for Parkinson’s Disease

Drugs in the Pipeline for Schizophrenia

Bipolar Disorder Overview
Drugs in the Pipeline for Attention Deficit Hyperactivity Disorder (ADHD)

Drugs in the Pipeline for Autism

Drugs in the Pipeline for Sleep Disorders

5 DRUGS IN THE PIPELINE FOR CANCER

Corporate Research in Cancer

Cancer Vaccines from Adult Tissue Stem Cells

Avi Antisense Drug Boosts Cancer Chemotherapy

Genvec Tnf Gene Therapy for Pancreatic Cancer

PDL Gets License Fees for Humanized Antibodies
Abgenix/Amgen Colorectal Cancer Pivotal Clinical

Dendreon Vaccine Extends Prostate Cancer Survival

Aphton Asks Australia for First Cancer Agent Ok

Genmab Asks for Ok To Start Lymphoma Clinicals
How Introgen’s INGN 241 Hits Cancers

Lymphoma Therapies Do Well in Clinical Trials

Entremed Compound Stabilizes Multiple Myeloma

Lymphoma Patients Respond to Genmab Monoclonal

Kimmel Center Vaccine is Promising in Mice

Enzon Negotiates to Develop a Targeted Cancer Agent

Allos Sensitizer Aids Brain Metastasis Radiation

AGY Therapeutics Finds Brain Cancer Target

Ariad Candidate Reduces Brain Tumor Cell Growth
Universities' Research in Cancer

Protein Might Contribute to Breast Cancer by Inhibiting Cell Growth

Peptide-based Scaffolds as Drug Delivery Vehicles

Cancer Drugs in the Pipeline

Gastrointestinal Cancer Drugs in the Pipeline

Breast Cancer Drugs in the Pipeline

Lung Cancer Drugs in the Pipeline

Prostate Cancer Drugs in the Pipeline

Lymphoma Drugs in the Pipeline

Skin Cancer Drugs in the Pipeline
6 PATENTS; COMPANY LISTING; CONTACT DETAILS

Some Important Patents

Patents Relating to Cardiovascular Therapeutics

Patents Relating to CNS Therapeutics

Patents Related to Cancer Therapeutics

Contacts

Companies

Universities and Research Institutes

7 FROST & SULLIVAN 2004 SCIENCE AND TECHNOLOGY AWARDS

Technology Innovation Award

Introduction

Award Recipient

Excellence in Technology Award

Introduction

Award Recipient

8 DECISION SUPPORT DATABASE

Decision Support Database
Pharmaceutical R&D Expenditure (Million USD)

Number of Biotechnology Companies by Region

Government Investment in Biotechnology

Government R&D Investment in Biotechnology as a Percentage of Total Government Healthcare Expenditure
Private Investment in Biotechnology (Million USD)

Private Investment in Biotechnology as a Percentage of Total Private Healthcare Expenditure
Number of European Biotechnology Patents Filed/Granted

Number of Neurologists

Number of Cardiologists

Number of Psychiatric Care Hospital Beds




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/364803

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 11/10/2008 06:59:48
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Drugs in the Pipeline--An R&D Analysis
Web Address:
http://www.researchandmarkets.com/reports/364803
Office Code:
OCHKELLMSSR

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License €3,365.00
Electronic (PDF) - Enterprisewide €4,475.00
Electronic and Hard Copy (PDF) - Enterprisewide €4,845.00 + EUR€ 50.00 Shipping/Handling *
Electronic and Hard Copy (PDF) - Site License €3,735.00 + EUR€ 50.00 Shipping/Handling *

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 11/10/2008 06:59:48

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World